Results 111 to 120 of about 98,202 (223)
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu +5 more
wiley +1 more source
CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li +8 more
wiley +1 more source
Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto +2 more
wiley +1 more source
Lung cancer (LC) remains the leading cause of global cancer‐related death. Phytochemicals from medicinal plants are increasingly being considered as potential LC treatment agents due to their multi‐targeted action, safety, and accessibility. These have anticancer properties by regulating key molecular signaling pathways.
Md. Rezaul Islam +14 more
wiley +1 more source
Abstract Ninety percent of all primary liver malignancies are hepatocellular carcinomas (HCC), making liver cancer the third most common cause of cancer‐associated mortality. Different patterns of programmed cell death (PCD) are crucial for the survival of tumors, and they might serve as a prognostic marker for HCC.
Lin Ding +10 more
wiley +1 more source
Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao +6 more
wiley +1 more source
PHF1 is a known epigenetic regulator involved in transcriptional silencing in cancer. In this study, we identified PHF1 as an oncogene that promotes PDAC progression and demonstrated that its inhibition induces ferroptosis. Mechanistically, PHF1 physically interacts with the FBL/NOP56/NOP58 snoRNP complex to enhance the IRES‐dependent translation of ...
Yujiao Xie +9 more
wiley +1 more source
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska +2 more
wiley +1 more source
ABSTRACT Succinylation has been shown to promote lung cancer development, but its mechanism remains incompletely understood. KAT2A, a succinyltransferase, acts as an oncogene in multiple cancers, but its role in mediating lung cancer progression is unclear.
Junping Li +7 more
wiley +1 more source
Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley +1 more source

